INSULET CORP
Fiscal years labelled by the calendar year in which they end. Bars in $ billions; per-share figures as reported.
CAPITALIZATION 12/31/25
| ($ millions) | Amount | % |
|---|---|---|
| Total debt | 949 | 38.5 |
| Stockholders' equity | 1,515 | 61.5 |
| Total capitalization | 2,464 | 100.0 |
69,354,199 shares outstanding at 29 July 2026 (cover page of the 10-Q filed 5 August 2026).
LONG-TERM DEBT 12/31/25
| ($ millions) | Amount |
|---|---|
| Long-term debt, incl. current maturities | 949 |
| Long-term debt, noncurrent | 931 |
| Current maturities | 18 |
CAPITAL STOCK 12/31/25
| Common shares authorized | 100,000,000 |
| Common shares issued | 70,588,192 |
| Treasury shares | 197,374,000 |
| Par or stated value per share ($) | 0.001 |
| Preferred stock ($ millions) | 0 |
| Outstanding at 7/29/26 | 69,354,199 |
DIVIDENDS DECLARED/PAID
| Fiscal year | Per share $ | Payout % |
|---|---|---|
| 2025 | – | – |
| 2024 | – | – |
| 2023 | – | – |
| 2022 | – | – |
| 2021 | – | – |
HISTORY AND BUSINESS
HISTORY: Incorporated in Delaware.
BUSINESS: Classified by the SEC under Standard Industrial Classification 3841, Surgical & Medical Instruments & Apparatus. Large accelerated filer. Principal executive office: 100 Nagog Park, Acton, MA 01720. Fiscal year ends December 31. For a description of the business, see Item 1 of the latest 10-K.
CONSOLIDATED INCOME ACCOUNT, YEARS ENDED
| ($ millions) | 12/31/25 | 12/31/24 | 12/31/23 |
|---|---|---|---|
| Revenues | 2,708 | 2,072 | 1,697 |
| Cost of revenues | 768 | 626 | 537 |
| Gross profit | 1,940 | 1,446 | 1,160 |
| Research and development | 301 | 220 | 205 |
| Selling, general and administrative | 1,165 | 917 | 735 |
| Depreciation and amortization | 90 | 81 | 73 |
| Operating income | 474 | 309 | 220 |
| Interest expense | 59 | 43 | 36 |
| Income before income taxes | 340 | 300 | 215 |
| Income taxes | 92 | (118) | 8 |
| Net income | 247 | 418 | 206 |
| Earned per share, diluted ($) | 3.48 | 5.78 | 2.94 |
| Dividends per share ($) | – | – | – |
CONSOLIDATED BALANCE SHEET
| ($ millions) | 12/31/25 | 12/31/24 |
|---|---|---|
| Inventories | 453 | 430 |
| Total current assets | 1,914 | 1,891 |
| Property, plant and equipment, net | 820 | 723 |
| Goodwill | 52 | 52 |
| Total assets | 3,190 | 3,088 |
| Total current liabilities | 680 | 528 |
| Long-term debt | 931 | 1,296 |
| Total liabilities | 1,675 | 1,876 |
| Stockholders' equity | 1,515 | 1,212 |
| Total liabilities and equity | 3,190 | 3,088 |
TEN-YEAR STATISTICS: FISCAL YEARS ($ millions except per share)
| Fiscal year ended | Revenues | Oper. income | Net income | Net margin % | EPS diluted $ | Div. per share $ | Oper. cash flow | Capital expend. | Free cash flow | Total assets | Total liabilities | Total debt | Stockholders' equity | ROE % | Debt / equity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12/31/25 | 2,708 | 474 | 247 | 9.1 | 3.48 | – | 569 | 192 | 378 | 3,190 | 1,675 | 949 | 1,515 | 16.3 | 0.63 |
| 12/31/24 | 2,072 | 309 | 418 | 20.2 | 5.78 | – | 430 | 125 | 305 | 3,088 | 1,876 | 1,380 | 1,212 | 34.5 | 1.14 |
| 12/31/23 | 1,697 | 220 | 206 | 12.2 | 2.94 | – | 146 | 76 | 70 | 2,588 | 1,856 | 1,416 | 733 | 28.2 | 1.93 |
| 12/31/22 | 1,305 | 38 | 5 | 0.4 | 0.07 | – | 119 | 123 | (4) | 2,251 | 1,775 | 1,402 | 476 | 1.0 | 2.94 |
| 12/31/21 | 1,099 | 126 | 17 | 1.5 | 0.24 | – | (68) | 112 | (180) | 2,049 | 1,492 | 1,274 | 556 | 3.0 | 2.29 |
| 12/31/20 | 904 | 52 | 7 | 0.8 | 0.10 | – | 84 | 129 | (45) | 1,873 | 1,269 | 1,059 | 604 | 1.1 | 1.75 |
| 12/31/19 | 738 | 50 | 12 | 1.6 | 0.19 | – | 98 | 164 | (65) | 1,143 | 1,067 | 888 | 76 | 15.3 | 11.70 |
| 12/31/18 | 564 | 27 | 3 | 0.6 | 0.05 | – | 36 | 157 | (122) | 929 | 717 | 592 | 212 | 1.6 | 2.79 |
| 12/31/17 | 464 | (7) | (27) | -5.8 | (0.46) | – | 41 | 74 | (32) | 817 | 658 | 566 | 158 | -16.9 | 3.57 |
| 12/31/16 | 367 | (11) | (29) | -7.9 | (0.48) | – | 16 | 22 | (6) | 457 | 393 | 333 | 63 | -45.8 | 5.27 |
Net margin = net income ÷ revenues; ROE = net income ÷ year-end stockholders’ equity; total debt = long-term debt including current maturities plus short-term borrowings/commercial paper, as tagged in XBRL; free cash flow = operating cash flow − purchases of property, plant and equipment; d = derived as total assets − total equity where the filing does not tag total liabilities; – = not reported in XBRL for that year.
REGISTRANT:
INSULET CORP
CIK 1145197 · EIN 04-3523891
PRINCIPAL OFFICE:
100 Nagog Park, Acton, MA 01720
Tel.: 978-600-7000
INCORPORATED:
Delaware
INDUSTRY (SEC SIC CODE):
3841 · Surgical & Medical Instruments & Apparatus
FILER STATUS:
Large accelerated filer
LATEST ANNUAL REPORT:
10-K for period ended 12/31/25, filed 18 February 2026
Sources: SEC XBRL company facts (all financial figures) · SEC submissions (registrant, address, SIC, filings) · annual reports: 10-K FY2025 (filed 2/18/26) · 10-K FY2024 (filed 2/21/25) · 10-K FY2023 (filed 2/23/24) · 10-K FY2022 (filed 2/24/23) · 10-K FY2021 (filed 2/24/22) · 10-K FY2020 (filed 2/24/21) · 10-K FY2019 (filed 2/26/20) · 10-K FY2018 (filed 2/26/19). Values are the latest figures filed for each fiscal year (restated where a later 10-K restated them). Ratios and free cash flow are Pathos calculations from those figures. Retrieved 31 October 2026.
Data from SEC filings. © 2026 Pathos Investments · pathosinvestments.com · For educational purposes only. Not investment advice.